Company profile: Acurx Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of clinical-stage antibiotics for difficult-to-treat infections, including ibezapolstat, an antibiotic in Phase 2b for C. difficile infection showing promise in clinical cure and sustained clinical cure with potential microbiome benefits, and ACX-375C, a preclinical program developing systemic Gram-positive selective-spectrum antibiotics targeting multi-drug resistant and sensitive pathogens.
Products and services
- ACX-375C Program: A preclinical Gram-positive selective spectrum systemic antibiotic program that architects agents targeting multidrug-resistant and sensitive Gram-positive bacterial pathogens
- Acurx Antibiotic Development: A clinical-stage biopharmaceutical initiative that develops new antibiotics for difficult-to-treat infections, producing therapeutic products aligned with ibezapolstat and ACX-375C
- Ibezapolstat: A Phase 2b antibiotic engineered to treat Clostridioides difficile infection, demonstrating clinical cure and sustained clinical cure with potential microbiome benefits
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Acurx Pharmaceuticals
Mucosis
HQ: The Netherlands
Website
- Description: Provider of clinical-stage mucosal vaccines delivered needle-free via the nose or mouth, including SynGEM®, an intranasal vaccine candidate to prevent respiratory syncytial virus infection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mucosis company profile →
Topaz Pharmaceuticals
HQ: United States
Website
- Description: Provider of pharmaceutical products for children's health, offering drugs to treat head lice, acne, and infections, as well as vaccines against childhood diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Topaz Pharmaceuticals company profile →
Immtech Pharma
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics, focusing on the discovery and commercialization of treatments for patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immtech Pharma company profile →
GeneOhm
HQ: United States
Website
- Description: Provider of nucleic acid-based diagnostic solutions, designing, developing, and delivering systems addressing unmet diagnostic needs across inherited disease, infectious disease, and oncology, including rapid nucleic acid-based systems to detect and identify infectious agents.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeneOhm company profile →
Jaguar Health
HQ: United States
Website
- Description: Provider of plant-based prescription medicines for urgent global health needs, including Crofelemer, an oral therapy for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, being studied for cancer therapy–related diarrhea and short bowel syndrome with intestinal failure; Canalevia-CA1 for chemotherapy-induced diarrhea in dogs; and NP-300, an investigational antisecretory for cholera-related diarrhea.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jaguar Health company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Acurx Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Acurx Pharmaceuticals
2.2 - Growth funds investing in similar companies to Acurx Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Acurx Pharmaceuticals
4.2 - Public trading comparable groups for Acurx Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →